Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDAKNASDAQ:ONVONYSE:SQZNASDAQ:TROV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDAKCodiak BioSciences$0.00$0.00$0.05▼$6.98$59K3.711.37 million shsN/AONVOOrganovo$3.94$1.56▼$21.96$3.47M1.13617,505 shs243,634 shsSQZSQZ Biotechnologies$0.03$0.03$0.25▼$3.56$826K2.34455,220 shs151 shsTROVCardiff Oncology$2.75+3.4%$16.75$0.70▼$3.46$30.28M1.04648,892 shs797,423 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDAKCodiak BioSciences0.00%0.00%0.00%0.00%0.00%ONVOOrganovo0.00%0.00%+22.89%-50.91%-81.60%SQZSQZ Biotechnologies0.00%0.00%0.00%-6.67%+5.66%TROVCardiff Oncology0.00%-5.67%+11.76%-41.92%-21.53%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCDAKCodiak BioSciences0.7439 of 5 stars0.00.00.04.60.61.70.6ONVOOrganovo0.183 of 5 stars0.03.00.00.00.60.00.6SQZSQZ BiotechnologiesN/AN/AN/AN/AN/AN/AN/AN/ATROVCardiff OncologyN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDAKCodiak BioSciences 0.00N/AN/AN/AONVOOrganovo 0.00N/AN/AN/ASQZSQZ Biotechnologies 0.00N/AN/AN/ATROVCardiff Oncology 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDAKCodiak BioSciences$33.57M0.00N/AN/A$2.39 per share0.00ONVOOrganovo$122K0.00N/AN/A$0.02 per share0.00SQZSQZ Biotechnologies$18.16M0.05N/AN/A$1.94 per share0.01TROVCardiff Oncology$250K121.12N/AN/A$0.94 per share2.93Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDAKCodiak BioSciences-$37.16M-$0.69N/A∞N/A-51.13%-109.51%-34.44%N/AONVOOrganovo-$14.67M-$10.20N/AN/AN/A-10,151.64%-346.26%-187.53%5/30/2025 (Estimated)SQZSQZ Biotechnologies-$79.46M-$2.61N/AN/AN/A-369.96%-119.83%-59.90%N/ATROVCardiff Oncology-$16.41M-$2.80N/A∞N/A-3,688.31%-202.00%-122.92%N/ALatest TROV, ONVO, SQZ, and CDAK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/19/2025Q3 2025ONVOOrganovo-$2.52-$2.28+$0.24-$0.19$0.05 million$0.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCDAKCodiak BioSciencesN/AN/AN/AN/AN/AONVOOrganovoN/AN/AN/AN/AN/ASQZSQZ BiotechnologiesN/AN/AN/AN/AN/ATROVCardiff OncologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDAKCodiak BioSciences0.664.244.24ONVOOrganovoN/A0.721.72SQZSQZ BiotechnologiesN/A3.503.50TROVCardiff Oncology0.122.372.37Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDAKCodiak BioSciences71.30%ONVOOrganovo8.23%SQZSQZ Biotechnologies38.51%TROVCardiff Oncology9.99%Insider OwnershipCompanyInsider OwnershipCDAKCodiak BioSciences8.20%ONVOOrganovo3.72%SQZSQZ Biotechnologies16.00%TROVCardiff Oncology0.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDAKCodiak BioSciences10236.83 million33.81 millionNot OptionableONVOOrganovo201.70 million14.79 millionOptionableSQZSQZ Biotechnologies1,62029.49 million24.77 millionNot OptionableTROVCardiff OncologyN/A11.01 millionN/ANot OptionableTROV, ONVO, SQZ, and CDAK HeadlinesRecent News About These CompaniesWhy Cardiff Oncology, Inc.’s (CRDF) Stock Is Up 6.08%April 29, 2025 | aaii.comCardiff Oncology announces second patent for onvansertib combinationApril 24, 2025 | markets.businessinsider.comCardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve PatientsApril 23, 2025 | tmcnet.comCardiff Oncology (NASDAQ:CRDF) Stock, Option ChainApril 23, 2025 | benzinga.comIs Cardiff Oncology, Inc. (CRDF) The Hot Biotech Stock Under $5?March 26, 2025 | insidermonkey.comCardiff Oncology’s Earnings Call: Optimism Amid ChallengesFebruary 28, 2025 | tipranks.comWilliam Blair Keeps Their Buy Rating on Cardiff Oncology (CRDF)February 27, 2025 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: TransMedics Group (TMDX) and Cardiff Oncology (CRDF)February 27, 2025 | markets.businessinsider.comWhy Cardiff Oncology, Inc.’s (CRDF) Stock Is Up 15.07%January 31, 2025 | aaii.comCardiff Oncology Inc (CRDF) Stock: More Robust Than the Numbers Suggest?December 14, 2024 | bovnews.comCardiff Oncology Inc (CRDF) Stock: Surpassing Expectations in the Market?December 14, 2024 | bovnews.comCardiff Oncology announces positive colorectal data and $40m stock oversubscriptionDecember 11, 2024 | msn.comCardiff unveils positive Phase 2 data for colorectal cancer drug, $40M offeringDecember 10, 2024 | endpts.comCardiff stock soars on onvansertib data, $40M direct offeringDecember 10, 2024 | msn.comCardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct OfferingDecember 10, 2024 | tmcnet.comStock Surge, Strong Data: Is Cardiff Oncology (CRDF) on the Brink of a Major Breakthrough?December 10, 2024 | bovnews.comCardiff Oncology Reports Positive Q3 2024 Results and Clinical ProgressNovember 9, 2024 | markets.businessinsider.comCardiff Oncology Reports Third Quarter 2024 Results and Provides Business UpdateNovember 8, 2024 | markets.businessinsider.comWhat’s Fueling Cardiff Oncology Inc (CRDF) Stock’s 7.23% Gain Above Its 200-Day SMA?November 2, 2024 | bovnews.comWhat’s Driving Cardiff Oncology Inc (CRDF) Stock’s 16.85% Surge Over the Past Month?November 1, 2024 | bovnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Why D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumGold Rally Continues: These 3 Mining Stocks Are Likely to BenefitBy Chris Markoch | April 16, 2025View Gold Rally Continues: These 3 Mining Stocks Are Likely to Benefit2 Smart Investments to Follow Warren Buffett’s LeadBy Ryan Hasson | April 23, 2025View 2 Smart Investments to Follow Warren Buffett’s LeadT-Mobile US: The Un-Carrier Is an Indisputable Buy on the Dip By Jea Yu | April 29, 2025View T-Mobile US: The Un-Carrier Is an Indisputable Buy on the Dip TROV, ONVO, SQZ, and CDAK Company DescriptionsCodiak BioSciences NASDAQ:CDAKCodiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Organovo NASDAQ:ONVOOrganovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.SQZ Biotechnologies NYSE:SQZ$0.03 0.00 (0.00%) As of 05/9/2025SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.Cardiff Oncology NASDAQ:TROVCardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready Why DraftKings Share Price Could Soar to Multi-Year Highs BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
